Cyano-Substituted FGFR4 Inhibitors for Mutant-Resistant Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small-molecule inhibitors targeting FGFR4 kinase domain are limited by structural differences from FGFR1-3, leading to reduced efficacy against FGFR4 and drug resistance due to mutations like V550L, necessitating the development of highly selective and potent FGFR4 inhibitors.
Innovation Solution
A compound represented by formula (I) or its pharmaceutically acceptable salts, isomers, hydrates, or prodrugs, specifically designed to target FGFR4, with varying substituents and linkages to enhance selectivity and inhibit FGFR4 activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing small molecule inhibitors are designed to target FGFR1-3 kinase domains, then they can effectively inhibit FGFR1/2/3, but they do not work well against FGFR4 due to structural differences
Solution Approach 1:
The patent applies local quality by designing specific molecular features in the inhibitor compound that selectively interact with unique structural characteristics of FGFR4 kinase domain. The compound contains specific substituent groups and spatial arrangements that match the local structural features of FGFR4, allowing selective binding while maintaining inhibition capability.
Solution Approach 2:
The patent employs parameter changes by modifying key structural parameters of the inhibitor molecule, including substituent types, linkage configurations, and spatial orientation. These parameter modifications enable the compound to adapt to the structural differences between FGFR4 and FGFR1-3, achieving selective inhibition of FGFR4.
2Adaptability or versatility
If inhibitors are designed with high selectivity for FGFR4, then they can overcome structural differences, but they face reduced efficacy due to mutations like V550L
Solution Approach 1:
The patent applies dynamics by designing a flexible inhibitor molecule with adaptable binding modes. The compound can adjust its conformation and interaction pattern to accommodate structural variations caused by mutations such as V550L, maintaining binding affinity and inhibition efficacy across different FGFR4 variants.
Solution Approach 2:
The patent employs universality by creating a multi-functional inhibitor compound that can interact with multiple residues and structural features of FGFR4 kinase domain. This multi-functional design allows the single compound to effectively inhibit both wild-type and mutated forms of FGFR4, overcoming the limitation of mutation-induced resistance.
3Ease of manufacture
If conventional inhibitor structures are used, then synthesis is straightforward, but they lack the specificity needed for FGFR4 inhibition
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional modules or segments, each with a specific role in binding to FGFR4. This modular structure maintains relative synthesis simplicity while enabling precise control over the overall molecular properties and selectivity through controlled assembly of segments.
Data Source
AI summary
A cyano-substituted pyridine and cyano-substituted pyrimidine compound and a preparation method therefor and an application thereof, which specifically relate to a compound represented by formula (I) and an isomer, a hydrate, a solvate, a pharmaceutically acceptable salt, and a prodrug thereof, and a preparation method therefor and an application thereof in the preparation of a drug as a kinase inhibitor. The compound has good inhibitory activity against kinases such as FGFR4 and mutant FGFR4V550L.